First Steps: Neurodegeneration
==============================

Since the beginning of the 20th century relentlessly progressive neurological diseases have classically been attributed to a primary neuronal dysfunction. This affirmation applies to Parkinson disease (PD), Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), among others ([@B31]; [@B24]). Therefore, most investigations have been carried out under this belief, leading to the coining of the term "neurodegeneration." This paradigm was later on applied to psychiatric diseases such as Schizophrenia and Major depression ([@B18]; [@B11]). As a result of those efforts, a detailed description of neurons' characteristics in the main affected areas in those diseases as well as a broadening of the knowledge of neuronal functioning was achieved. Since then, several physiopathological hypotheses were constructed; notwithstanding that when put into practice by therapeutical testing, results have not met the expectations ([@B25]; [@B5]).

In the 90s, a new era began that considered the possibility of a more important role of the so far neglected neuroglia. This led to different findings opposed to the belief of the astrocytes sole function being neuronal structural support.

Astrocytes have been found to have a much more active role that the one predicted by the earlier guessers. Particularly, they are involved in the ions exchange with neurons, they are organized as a syncytium that allows them to interchange information with other astrocytes residing in a defined net through different types of Ca^+++^ signals while regulating the release of signaling molecules involved in the production of trophic factors, transmitters and transporters that when released to the extracellular medium will modulate the synaptic activity synchronizing the neuronal functions. Also they are involved in the extracellular K^+^ uptake, in synaptogenesis and gene expression; adapting, at the same time, the permeability of the blood--brain barrier to the neuronal and synaptic needs ([@B36]; [@B15]; [@B35]; [@B21]). A more exhaustive description of the astrocytes properties and functions is beyond the scope of this mini review and is detailed elsewhere ([@B42]).

The New Era: Primary Degenerative Disorders
===========================================

Slowly but relentlessly, the results of several studies confirmed the existence of an active role played not only by the astrocytes but also by microglia. Mounting evidence suggests that astrocytes modulate microglial response, through the establishment of a complex cross-talk between both types of cells mediated by the production of different chemokines and cytokines ([@B9]; [@B39]). Therefore, we think that the broader term primary degenerative disorders of the central nervous system (PDD CNS) alludes to the complex pathology of these diseases (in contrast to the classic term neurodegeneration) and will be used henceforward in this article.

Astrocytic findings in the PDDs include:

In FTD, the classic approach subdivided the frontotemporal anatomic atrophy with regards to the concomitant histopathological findings, that is: Pick disease when tau-positive intraneuronal inclusions were found, FTD with motor neuron disease when tau-negative-ubiquitine-positive intracellular inclusions were present in motor neurons or Frontotemporal Lobar Degeneration when no particular histopathological features were observed ([@B6]). On the contrary, recent studies have demonstrated that regardless of the presence or absence of the "classic" neuronal inclusions, clinical disease progression is associated with the extent of neuronal loss, the degree of extracellular microvacuolation and, regarding glial pathology, the level of both astrogliosis and astrocytic apoptosis ([@B6]; [@B20]).

With regards to PD, microgliosis has been found in a sustained fashion by different authors associated with the creation and maintenance of a vigorous inflammatory state at the substantia nigra pars compacta ([@B27]; [@B26]) and striatum, the latter of a strikingly similar characteristics in animal models and human brain samples ([@B8]). The mentioned state seems to be modulated by astrocytes, through the exocytosis of paracrine factors in the substantia nigra such as ICAM-1 and IL-6, which in turn act as stimulators of microglia migration ([@B27]).

Regarding AD, in a triple transgenic mouse model it has been shown that the presence of senile plaques in the hippocampus induces a mild astrocytic (and microglial) reaction within the Aβ plaques' periphery ([@B29]); a finding that was not observed in the entorhinal or prefrontal cortex ([@B51]; [@B22]). However, in human brain samples astroglial reaction, although present and with a clear hippocampal preference, seems to be less clearly associated with amyloid deposition at least in the lateral temporal cortex ([@B49]; [@B29]; [@B43]; [@B47], [@B45]; [@B51]; [@B32]).

Both in Major Depression and Schizophrenia there seems to be a mild astrocytic atrophy (characterized mainly by a decreased expression of GFAP) without a definitive consensus in relation to the stability of the total number of astrocytes ([@B46]; [@B48]). Moreover, in Schizoprhenia, several functional astrocytic changes have been described such as a diminished expression of EAAT1 and EAAT1 (human glutamate transporters) in the prefrontal cortex, augmented synthesis of condroitin sulfate proteoglycans in the amygdala and entorhinal cortex, altered metabolism of [D]{.smallcaps}-serine, elevated levels of kynurenic acid (NMDA inhibitor synthesized by astrocytes), etc. ([@B33]; [@B1]; [@B13]; [@B46]; [@B48]).

Finally, in ALS, astrogliosis both in white and gray matter is a very important hallmark of the illness all along its course ([@B50]; [@B23]; [@B41]). In the SOD1^G93A^ transgenic mouse model astroglial atrophy has been described restricted to the astrocytes associated with the affected motor neurons ([@B38]). Microglia activation is also increased in ALS and in another SOD1 mouse model [@B50] demonstrated that it could be modulated by the manipulation of astrocytic behavior ([@B50]; [@B23]; [@B41]).

Special Consideration
---------------------

A particular difficulty in the study of these diseases is that they mostly represent a deterioration of a highly evolved cognitive and/or motor functioning system. Therefore, and punctually in psychiatric illnesses, it seems that animal models are far from resembling all the peculiarities of the human diseases, even if the anatomopathological findings can be mimicked. On the other hand, human testing is ethically inappropriate for obvious reasons and therefore, the most representative research tool available is the study of post mortem human brains ([@B18]; [@B5]). Furthermore, since clinical diagnosis relies in a constellation of signs and symptoms that are secondary to a physiopathogenic process that is far from recently starting, the study of the disease early-stages is extremely difficult. All the above determines hazards to the methodological study approach of many hypotheses, particularly those involving disease onset and progression.

Temporality Clues
=================

We reviewed the international literature in order to find descriptions in human or animal models which may support the hypothesis that astrocyte pathology precedes neuronal damage (**Table [1](#T1){ref-type="table"}**).

###### 

Experimental findings suggestive of primary astrocytic damage.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease   Reference   Species             Findings
  --------- ----------- ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  FTD       [@B6]       Human               Astrocytic apoptosis is present at early stages and increases with disease progression.

            [@B20]      Human               Astrogliosis is present at early stages of the disease.

  PD        [@B17]      Mice                Astrocytic cytoplasmatic α-synuclein deposition precedes neuronal damage.

  AD        [@B29]      Mice (3xTg)         Hippocampal astroglia atrophy (6th month) precedes the extracellular Aβ deposition (12th month).

            [@B51]      Mice (3xTg)         Entorhinal astroglial atrophy (1st month) precedes neurodegeneration (12 months of age).

            [@B22]      Mice (3xTg)         Medial prefrontal astroglial atrophy (1 month of age) precedes neurodegeneration (12 months of age).

  AND       [@B34]      Mice                Hepatic encephalopathy: selective astrocyte swelling.

            [@B19]      Human Rats          Wernicke's encephalopathy: loss of EAAT1 and EAAT2 astrocytic glutamate transporters.

  ALS       [@B7]       Mice (SOD1^G85R^)   SOD1 astrocyte inclusions precede similar neuronal inclusions and later clinical signs.

            [@B38]      Mice (SOD1^G93A^)   Abnormal spheroid-shaped astrocytes (75th day) in the ventral horns of the lumbar spinal cord, astrogliosis of the ventral and dorsal horns before clinical sings and evident neuron number reduction (100th day).

            [@B30]      Rats (SOD1^G93A^)   Selective astrocytic mutation of SOD1^G93A^ leads to ALS signs.

            [@B44]      Rats                Selective astrocytic mutation of Tar DNA-binding protein 43 (TDP-43) leads to ALS signs.

  SCA       [@B10]      Mice                Bergman glia expressing ataxin-7 lead to SCA symptoms.

  HD        [@B12]      Mice Human          Selective expression of mutant Huntingtin in mice astrocytes leads to HD signs.\
                                            Astrogliosis in the dorsal stratum in two human brain samples without clinical symptoms (grade 0).

            [@B4]       Mice                Selective expression of mutant Huntingtin in mice astrocytes leads to HD signs.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FTD, Frontotemporal dementia; PD, Parkinson disease; AD, Alzheimer's disease; AND, Acquired neuropsychiatric disease; ALS, Amyotrophic lateral sclerosis; SCA, Spinocerebellar ataxia; HD, Huntington disease.

Human anatomical material is scarce regarding this point because cadaveric material, such as brains and spinal cords, belongs mostly to patients who at the time of their death were already at late stages of their pathological process.

However, there are some observations in animal experimentation, which situates astrocytic damage at the beginning of the pathological timeline. Examples are as follows:

Frontotemporal Dementia
-----------------------

In recent human studies astrocytes showing apoptotic signs were frequently found at the beginning of the disease when neuronal loss was yet very rare ([@B6]). Moreover, in a different study which focused on histological characteristics, astrogliosis was found to be present at early stages of the disease ([@B20]). In later-stage cases, astrocytic apoptosis markers increased while astrogliosis was found with less frequency ([@B6]; [@B20]). These findings support the notion that glial pathology occurs at the very starting of the illness besides being a major feature during the course of the disease.

Parkinson Disease
-----------------

In an extensive research done in human brains, [@B3] demonstrated that α-synuclein deposition involves a wider brain area than the one that becomes symptomatic and that these symptoms appear at a later stage on the course of the disease, once neurons become affected at a high percentage. Curiously, the cells that do develop changes at early stages of intracellular α-synuclein deposition are astrocytes. In animal models, the accumulation of astrocytic cytoplasmatic α-synuclein eventually leads not only to astrocytic dysfunction but also to microglia activation through the release of cytokines and chemokines. These changes, in turn, determine the injury and eventually the non-cell autonomous killing of neurons ([@B17]).

In addition, several of the proteins codified by the altered genes in autosomic recessive forms of hereditary PD (Parkin, PINK-1, DJ-1), are mainly concentrated in astrocytes ([@B27]; [@B17]).

Alzheimer Disease
-----------------

In one of the only two transgenic animal models that mimic both the plaque deposition and the neurofibrillary tangles observed in humans ([@B28]) it has been observed that the early-term and start of the mid-term stages of the illness are characterized by the presence of hippocampal astroglia atrophy (6 months of age). This period is followed by the appearance of Aβ plaques and neurodegeneration in association with the persistence of astrocyte atrophy as well as astrogliosis in the periplaque area ([@B29]). Moreover, in the same mouse model early astrocytic atrophy was also found in the entorhinal cortex at 1 month of age ([@B51]) and in the prefrontal dorsolateral cortex since the 3rd month of age ([@B22]), in both cases without later periplaque astrogliosis and preceding neuronal dysfunction by even broader lapses.

Acquired Neuropsychiatric Diseases
----------------------------------

In several acquired neuropsychiatric disorders such as hepatic encephalopathy, Wernicke encephalopathy and heavy metals encephalopathy astrocytes are the primary affected cells ([@B37]; [@B19]; [@B34]). Their dysfunction is believed to determine neuronal injury and eventually death through glutamate toxicity. Astrocytes are the only brain cells capable of metabolizing ammonia through the enzyme glutamine synthetase. However, the excessive concentration of ammonia in hepatic encephalopathy determines an uncommon availability of glutamate precursors as well as an increased production of reactive oxygen and nitrogen species which ultimately lead to astrocytic mitochondrial dysfunction ([@B34]).

Amyotrophic Lateral Sclerosis
-----------------------------

Several observations support the idea that there is an early if not primary astrocytic damage in this disease ([@B41]).

To begin with, it was observed that transplantation of mutated SOD 1 expressing glial progenitors, able to differentiate into astrocytes, into the spinal cord of wild type rats induce motor neurons degeneration and clinical symptoms *in vivo* ([@B30]; [@B44]).

Furthermore, [@B38] employing the transgenic mouse model expressing the human SOD1^G93A^, identified a degenerative process involving a subset of astrocytes confined to the microenvironment of the spinal motor neurons. More importantly, the time-course of appearance of these cells was at the 75th day of age, that is, before the loss of motor cells. Moreover, the quoted astrocyte degeneration and its consequences were experimentally slowed down by the injection of 2-methyl-6-pyridine, a selective antagonist to the mGluR5 glutamate receptor. Therefore, glutamate toxicity seems to have a major role in astrocyte and neuron degeneration in mutant SOD1^G93A^ mice. These findings are consistent with the previously reported selective up-regulation of mGluR5 in astrocytes in the ventral spinal cord of ALS patients ([@B2]).

Other notorious publication that has been referred to ever since is [@B7] description of findings in genetically induced ALS mice. In this experimental study, transgenic and control mice were sacrificed at different ages and their CNS analyzed. They noted that the first pathological findings were astrocytic cytoplasmic aggregates that were approximately 1 month later observed in neurons and which preceded the clinical disease onset by 2.5 months.

Spinocerebellar Ataxia (SCA)
----------------------------

[@B10] demonstrated that in the polyglutamine disease SCA7, Purkinje cells undergo non-cell-autonomous degeneration in transgenic animals. They generated mice expressing ataxin-7 only in Bergmann glia (a specialized type of cerebellum's astrocytes in close contact with Purkinje cells), which was sufficient to produce ataxia and neurodegeneration. In a similar fashion, [@B14] also demonstrated that transgenic mice expressing ataxin-7 with 92 glutamines repeats (92Q) in non-neural cells at the cerebellum promoted Purkinje cells' degeneration and therefore developed a dramatic neurological phenotype presenting as a gait ataxia and culminating in premature death despite the absence of its expression in Purkinje cells.

Huntington's Disease (HD)
-------------------------

In animal mouse models it was observed that mice expressing mutated Huntingtin (mhtt) in neurons show mild or no neurological sings, while mice expressing mhtt only in astrocytes have a reduced expression of astrocyte glutamate transporters and end up developing neurological deficits and an earlier neuronal death than when compared with control transgenic or wild-type mice ([@B16]; [@B4]).

These observations are also supported by cultures results, where co-culturing wild mice neurons with astrocytes that over-express mhtt have shown that neurons undergo apoptosis, once more suggesting that those astrocytes have a deleterious effect onto normal neurons ([@B40]).

In humans, [@B12] observed reactive astrocytosis in the dorsal striatum in grade 0 HD subjects, when no neuronal damage is still apparent, with dorso-ventral striatum progression through grade 4 specimens. Despite being only two 0 HD human brain samples, we believe that these findings deserve at least further investigation.

Conclusion
==========

It has broadly been observed an early astrocytic dysfunction in the PDDs of the CNS. In the present mini review, this concept has been exemplified in CNS at its whole length: starting in the spine or the brain stem in ALS patients, ascending to the midbrain in PD, the cerebellum in SCA-7, the striatum in HD, the hippocampus in AD, the prefrontal cortex in FTD and, finally, compromising in a more subtle fashion the whole cortical gray matter in SCZ.

We advocate that these observations obtained from different degenerative pathologies, but mostly from experimental animal studies, may be the trees from a forest characterized by primary astrocytic dysfunction as the main process starting them.

We believe that in these particular pathologies, investigations conducted on human brain samples are absolutely necessary to confirm and expand the findings achieved in animal studies. This is based on the fact that particularly in cognitive pathology, anatomopathological findings do not necessary correlate with clinical symptoms (hence the actual disease) and that healthy animals do not acquire the high mental functions later to be lost, and therefore their analysis does not necessarily represent the human reality.

As a non yet explored approach, were astrocytic dysfunction to be of a diffuse fashion, the classically end-stage affected brain areas could be the ones to harbor early astrocytic pathology without neuron disease. Were astrocytic pathology to be restricted to a focused cerebral region, early changes in already symptomatic patients are unlikely to be studied although Parkinson and Alzheimer's disease may be the exceptions due to their known sequence of progression.

We support the idea that a study with human samples focused in the context of the different diseases so far mentioned might allow to ascertain through detailed description characteristics previously overlooked, thus obtaining hints of a paradigmatic physiopathological process in which the astrocytes might be the main players.
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